Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial.

Lichtenegger FS, Schnorfeil FM, Rothe M, Deiser K, Altmann T, Bücklein VL, Köhnke T, Augsberger C, Konstandin NP, Spiekermann K, Moosmann A, Boehm S, Boxberg M, Heemskerk MH, Goerlich D, Wittmann G, Wagner B, Hiddemann W, Schendel DJ, Kvalheim G, Bigalke I, Subklewe M.

Clin Transl Immunology. 2020 Mar 3;9(3):e1117. doi: 10.1002/cti2.1117. eCollection 2020.

2.

Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma - a case report.

Issels RD, Lindner LH, von Bergwelt-Baildon M, Lang P, Rischpler C, Diem H, Mosetter B, Eckl J, Schendel DJ, Salat C, Stötzer O, Burdach S, von Luettichau-Teichert I, Handgretinger R, Neumann J, Kirchner T, Steiger K, Boxberg M, Mansmann U, Multhoff G, Noessner E.

Int J Hyperthermia. 2020;37(1):55-65. doi: 10.1080/02656736.2019.1709666.

PMID:
31918587
3.

Machine Learning for Cancer Immunotherapies Based on Epitope Recognition by T Cell Receptors.

Mösch A, Raffegerst S, Weis M, Schendel DJ, Frishman D.

Front Genet. 2019 Nov 19;10:1141. doi: 10.3389/fgene.2019.01141. eCollection 2019. Review.

4.

Expitope 2.0: a tool to assess immunotherapeutic antigens for their potential cross-reactivity against naturally expressed proteins in human tissues.

Jaravine V, Mösch A, Raffegerst S, Schendel DJ, Frishman D.

BMC Cancer. 2017 Dec 28;17(1):892. doi: 10.1186/s12885-017-3854-8.

5.

Induction of porcine-specific regulatory T cells with high specificity and expression of IL-10 and TGF-β1 using baboon-derived tolerogenic dendritic cells.

Li M, Eckl J, Abicht JM, Mayr T, Reichart B, Schendel DJ, Pohla H.

Xenotransplantation. 2018 Jan;25(1). doi: 10.1111/xen.12355. Epub 2017 Oct 22.

PMID:
29057512
6.

Unbiased Identification of T-Cell Receptors Targeting Immunodominant Peptide-MHC Complexes for T-Cell Receptor Immunotherapy.

Lorenz FKM, Ellinger C, Kieback E, Wilde S, Lietz M, Schendel DJ, Uckert W.

Hum Gene Ther. 2017 Dec;28(12):1158-1168. doi: 10.1089/hum.2017.122. Epub 2017 Sep 26.

7.

A novel and effective method to generate human porcine-specific regulatory T cells with high expression of IL-10, TGF-β1 and IL-35.

Li M, Eckl J, Geiger C, Schendel DJ, Pohla H.

Sci Rep. 2017 Jun 21;7(1):3974. doi: 10.1038/s41598-017-04322-3.

8.

Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.

Schlenker R, Olguín-Contreras LF, Leisegang M, Schnappinger J, Disovic A, Rühland S, Nelson PJ, Leonhardt H, Harz H, Wilde S, Schendel DJ, Uckert W, Willimsky G, Noessner E.

Cancer Res. 2017 Jul 1;77(13):3577-3590. doi: 10.1158/0008-5472.CAN-16-1922. Epub 2017 May 22.

9.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH.

J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. Review.

10.

Assessment of cancer and virus antigens for cross-reactivity in human tissues.

Jaravine V, Raffegerst S, Schendel DJ, Frishman D.

Bioinformatics. 2017 Jan 1;33(1):104-111. doi: 10.1093/bioinformatics/btw567. Epub 2016 Sep 10.

PMID:
27614350
11.

T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.

Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann JH, Thiele F, Bohne F, Wisskirchen K, Wilde S, Sprinzl MF, Schendel DJ, Krackhardt AM, Uckert W, Wohlleber D, Schiemann M, Stemmer K, Heikenwälder M, Busch DH, Richter G, Mann M, Protzer U.

Gastroenterology. 2015 Oct;149(4):1042-52. doi: 10.1053/j.gastro.2015.05.055. Epub 2015 Jun 5.

PMID:
26052074
12.

Codon optimization of the human papillomavirus E7 oncogene induces a CD8+ T cell response to a cryptic epitope not harbored by wild-type E7.

Lorenz FK, Wilde S, Voigt K, Kieback E, Mosetter B, Schendel DJ, Uckert W.

PLoS One. 2015 Mar 23;10(3):e0121633. doi: 10.1371/journal.pone.0121633. eCollection 2015.

13.

Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice.

Obenaus M, Leitão C, Leisegang M, Chen X, Gavvovidis I, van der Bruggen P, Uckert W, Schendel DJ, Blankenstein T.

Nat Biotechnol. 2015 Apr;33(4):402-7. doi: 10.1038/nbt.3147. Epub 2015 Mar 16.

PMID:
25774714
14.

Expitope: a web server for epitope expression.

Haase K, Raffegerst S, Schendel DJ, Frishman D.

Bioinformatics. 2015 Jun 1;31(11):1854-6. doi: 10.1093/bioinformatics/btv068. Epub 2015 Feb 1.

PMID:
25644270
15.

Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.

Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger JC, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner G, Klein C, Bourquin C, Endres S.

J Natl Cancer Inst. 2014 Nov 24;107(1):364. doi: 10.1093/jnci/dju364. Print 2015 Jan.

PMID:
25424197
16.

New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia.

Subklewe M, Geiger C, Lichtenegger FS, Javorovic M, Kvalheim G, Schendel DJ, Bigalke I.

Cancer Immunol Immunother. 2014 Oct;63(10):1093-103. doi: 10.1007/s00262-014-1600-5. Epub 2014 Sep 4. Review.

PMID:
25186611
17.

CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.

Gassenmaier M, Chen D, Buchner A, Henkel L, Schiemann M, Mack B, Schendel DJ, Zimmermann W, Pohla H.

Stem Cells. 2013 Aug;31(8):1467-76. doi: 10.1002/stem.1407.

18.
19.

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA.

J Immunother. 2013 Feb;36(2):133-51. doi: 10.1097/CJI.0b013e3182829903.

20.

High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination.

Pohla H, Buchner A, Stadlbauer B, Frankenberger B, Stevanovic S, Walter S, Frank R, Schwachula T, Olek S, Kopp J, Willimsky G, Stief CG, Hofstetter A, Pezzutto A, Blankenstein T, Oberneder R, Schendel DJ.

Mol Med. 2013 Feb 8;18:1499-508. doi: 10.2119/molmed.2012.00221.

21.
22.

Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.

Nagel D, Spranger S, Vincendeau M, Grau M, Raffegerst S, Kloo B, Hlahla D, Neuenschwander M, Peter von Kries J, Hadian K, Dörken B, Lenz P, Lenz G, Schendel DJ, Krappmann D.

Cancer Cell. 2012 Dec 11;22(6):825-37. doi: 10.1016/j.ccr.2012.11.002.

23.

Is it time to abandon RHAMM/HMMR as a candidate antigen for immunotherapy of acute myeloid leukemia?

Schendel DJ.

Haematologica. 2012 Oct;97(10):1454-5. doi: 10.3324/haematol.2012.077099. No abstract available.

24.

CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells.

Lichtenegger FS, Mueller K, Otte B, Beck B, Hiddemann W, Schendel DJ, Subklewe M.

PLoS One. 2012;7(9):e44266. doi: 10.1371/journal.pone.0044266. Epub 2012 Sep 4.

25.

Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedure.

Wilde S, Geiger C, Milosevic S, Mosetter B, Eichenlaub S, Schendel DJ.

Oncoimmunology. 2012 Mar 1;1(2):129-140.

26.

Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition.

Wilde S, Sommermeyer D, Leisegang M, Frankenberger B, Mosetter B, Uckert W, Schendel DJ.

J Immunol. 2012 Jul 15;189(2):598-605. doi: 10.4049/jimmunol.1102165. Epub 2012 Jun 11.

27.

TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.

Spranger S, Jeremias I, Wilde S, Leisegang M, Stärck L, Mosetter B, Uckert W, Heemskerk MH, Schendel DJ, Frankenberger B.

Blood. 2012 Apr 12;119(15):3440-9. doi: 10.1182/blood-2011-06-357939. Epub 2012 Feb 27.

PMID:
22371883
28.

NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo.

Spranger S, Frankenberger B, Schendel DJ.

J Transl Med. 2012 Feb 25;10:30. doi: 10.1186/1479-5876-10-30.

29.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

30.

Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission.

Beck B, Dörfel D, Lichtenegger FS, Geiger C, Lindner L, Merk M, Schendel DJ, Subklewe M.

J Transl Med. 2011 Sep 13;9:151. doi: 10.1186/1479-5876-9-151.

31.

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.

Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML.

Clin Cancer Res. 2011 May 15;17(10):3064-76. doi: 10.1158/1078-0432.CCR-10-2234. Epub 2011 May 10. Review.

32.

Third generation dendritic cell vaccines for tumor immunotherapy.

Frankenberger B, Schendel DJ.

Eur J Cell Biol. 2012 Jan;91(1):53-8. doi: 10.1016/j.ejcb.2011.01.012. Epub 2011 Mar 25. Review.

PMID:
21439674
33.

The CD6 scavenger receptor is differentially expressed on a CD56 natural killer cell subpopulation and contributes to natural killer-derived cytokine and chemokine secretion.

Braun M, Müller B, ter Meer D, Raffegerst S, Simm B, Wilde S, Spranger S, Ellwart J, Mosetter B, Umansky L, Lerchl T, Schendel DJ, Falk CS.

J Innate Immun. 2011;3(4):420-34. doi: 10.1159/000322720. Epub 2010 Dec 18.

34.

Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study.

Westermann J, Flörcken A, Willimsky G, van Lessen A, Kopp J, Takvorian A, Jöhrens K, Lukowsky A, Schönemann C, Sawitzki B, Pohla H, Frank R, Dörken B, Schendel DJ, Blankenstein T, Pezzutto A.

Gene Ther. 2011 Apr;18(4):354-63. doi: 10.1038/gt.2010.143. Epub 2010 Nov 11.

PMID:
21068778
35.

MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors.

Leisegang M, Wilde S, Spranger S, Milosevic S, Frankenberger B, Uckert W, Schendel DJ.

J Clin Invest. 2010 Nov;120(11):3869-77. doi: 10.1172/JCI43437. Epub 2010 Oct 11.

36.

Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation.

Bürdek M, Spranger S, Wilde S, Frankenberger B, Schendel DJ, Geiger C.

J Transl Med. 2010 Sep 28;8:90. doi: 10.1186/1479-5876-8-90.

37.

Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.

Spranger S, Javorovic M, Bürdek M, Wilde S, Mosetter B, Tippmer S, Bigalke I, Geiger C, Schendel DJ, Frankenberger B.

J Immunol. 2010 Jul 1;185(1):738-47. doi: 10.4049/jimmunol.1000060. Epub 2010 May 28.

38.

T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.

Leisegang M, Turqueti-Neves A, Engels B, Blankenstein T, Schendel DJ, Uckert W, Noessner E.

Clin Cancer Res. 2010 Apr 15;16(8):2333-43. doi: 10.1158/1078-0432.CCR-09-2897. Epub 2010 Apr 6.

39.

Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.

Moosmann A, Bigalke I, Tischer J, Schirrmann L, Kasten J, Tippmer S, Leeping M, Prevalsek D, Jaeger G, Ledderose G, Mautner J, Hammerschmidt W, Schendel DJ, Kolb HJ.

Blood. 2010 Apr 8;115(14):2960-70. doi: 10.1182/blood-2009-08-236356. Epub 2010 Jan 26.

PMID:
20103780
40.

Diverse hematological malignancies including hodgkin-like lymphomas develop in chimeric MHC class II transgenic mice.

Raffegerst SH, Hoelzlwimmer G, Kunder S, Mysliwietz J, Quintanilla-Martinez L, Schendel DJ.

PLoS One. 2009 Dec 31;4(12):e8539. doi: 10.1371/journal.pone.0008539.

41.

Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.

Buchner A, Pohla H, Willimsky G, Frankenberger B, Frank R, Baur-Melnyk A, Siebels M, Stief CG, Hofstetter A, Kopp J, Pezzutto A, Blankenstein T, Oberneder R, Schendel DJ.

Hum Gene Ther. 2010 Mar;21(3):285-97. doi: 10.1089/hum.2008.192.

PMID:
19788391
42.

Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial.

Brill TH, Kübler HR, Pohla H, Buchner A, Fend F, Schuster T, van Randenborgh H, Paul R, Kummer T, Plank C, Eisele B, Breul J, Hartung R, Schendel DJ, Gansbacher B.

Hum Gene Ther. 2009 Dec;20(12):1641-51. doi: 10.1089/hum.2009.101.

PMID:
19671000
43.

Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity.

Wilde S, Sommermeyer D, Frankenberger B, Schiemann M, Milosevic S, Spranger S, Pohla H, Uckert W, Busch DH, Schendel DJ.

Blood. 2009 Sep 3;114(10):2131-9. doi: 10.1182/blood-2009-03-209387. Epub 2009 Jul 8.

PMID:
19587379
44.

Current use of room disinfectants and allergic symptoms at the age of 4 years.

Krauss-Etschmann S, Niedermaier S, Beyer J, Campoy C, Escolano V, Decsi T, Jakobik V, Schendel DJ, Demmelmair H, Heinrich J, Koletzko BV; NUHEAL Study Group.

J Allergy Clin Immunol. 2009 May;123(5):1176-8. doi: 10.1016/j.jaci.2009.01.054. Epub 2009 Apr 1. No abstract available.

PMID:
19342085
45.

Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.

Ebelt K, Babaryka G, Frankenberger B, Stief CG, Eisenmenger W, Kirchner T, Schendel DJ, Noessner E.

Eur J Cancer. 2009 Jun;45(9):1664-72. doi: 10.1016/j.ejca.2009.02.015. Epub 2009 Mar 21.

PMID:
19318244
46.

Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.

Geiger C, Nössner E, Frankenberger B, Falk CS, Pohla H, Schendel DJ.

J Mol Med (Berl). 2009 Jun;87(6):595-612. doi: 10.1007/s00109-009-0455-2. Epub 2009 Mar 7. Review.

PMID:
19271159
47.

Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells.

Javorovic M, Wilde S, Zobywalski A, Noessner E, Lennerz V, Wölfel T, Schendel DJ.

J Immunother. 2008 Jan;31(1):52-62.

PMID:
18157012
48.

Effects of galactooligosaccharide and long-chain fructooligosaccharide supplementation during pregnancy on maternal and neonatal microbiota and immunity--a randomized, double-blind, placebo-controlled study.

Shadid R, Haarman M, Knol J, Theis W, Beermann C, Rjosk-Dendorfer D, Schendel DJ, Koletzko BV, Krauss-Etschmann S.

Am J Clin Nutr. 2007 Nov;86(5):1426-37.

PMID:
17991656
49.

Decreased cord blood IL-4, IL-13, and CCR4 and increased TGF-beta levels after fish oil supplementation of pregnant women.

Krauss-Etschmann S, Hartl D, Rzehak P, Heinrich J, Shadid R, Del Carmen Ramírez-Tortosa M, Campoy C, Pardillo S, Schendel DJ, Decsi T, Demmelmair H, Koletzko BV; Nutraceuticals for Healthier Life Study Group.

J Allergy Clin Immunol. 2008 Feb;121(2):464-470.e6. Epub 2007 Nov 5.

PMID:
17980419
50.

Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma.

Ebelt K, Babaryka G, Figel AM, Pohla H, Buchner A, Stief CG, Eisenmenger W, Kirchner T, Schendel DJ, Noessner E.

Prostate. 2008 Jan 1;68(1):1-10.

PMID:
17948280

Supplemental Content

Loading ...
Support Center